ArticleDermatology and therapy2025

Baricitinib Provides Significant Improvements in Quality of Life and Functioning in Adults with Moderate-to-Severe Atopic Dermatitis with Baseline Body Surface Area ≤ 40% and Severe Itch.

Matthias Augustin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.